Aligos TherapeuticsALGS
13F holders, Q4 2025 (December 31)1holders
1new positions
0sold out
$9.32avg. 13F price*
At the end of Q4 2025, 1 institutions reported holding Aligos Therapeutics Inc. (ALGS) in their 13F filings, unchanged from Q4 2024. 1 opened new positions and 0 sold out. The largest holder was Triumph Capital Management ($1K).
- Company
- Aligos Therapeutics Inc.
- CUSIP
- 01626L105
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $1K |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q4 2025: 135 shares bought, net +135 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Triumph Capital Management | 0.00% | New | 135 | $1K |
"% of holder's portfolio" is ALGS's weight in each manager's 13F, not the share of Aligos Therapeutics Inc. the manager owns.